Pediatric cardiovascular drug dosing in critically ill children and extracorporeal membrane oxygenation

Journal of Cardiovascular Pharmacology

Volumn 58, Issue 2, 2011, Pages 126-132

  Watt, Kevin ^a   Li, Jennifer S ^a   Benjamin, Daniel K ^a   Cohen Wolkowiez, Michael ^a  

^a DUKE CLINICAL RESEARCH INSTITUTE   (United States)

Author keywords

cardiovascular agents; extracorporeal membrane oxygenation; pharmacokinetics; pharmacology

Indexed keywords

ADRENALIN; AMIODARONE; ANTIARRHYTHMIC AGENT; BUMETANIDE; DIURETIC AGENT; DOPAMINE; ESMOLOL; FUROSEMIDE; HYDRALAZINE; INOTROPIC AGENT; NESIRITIDE; NICARDIPINE; PROSTAGLANDIN E1; SILDENAFIL; VASODILATOR AGENT;

CARDIOGENIC SHOCK; CARDIOMYOPATHY; CARDIOVASCULAR DISEASE; CHILDHOOD DISEASE; CONGENITAL HEART MALFORMATION; CRITICALLY ILL PATIENT; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; ESSENTIAL HYPERTENSION; EXTRACORPOREAL OXYGENATION; HEART ARREST; HEART MUSCLE CONTRACTILITY; HUMAN; INTENSIVE CARE UNIT; LOADING DRUG DOSE; LOW DRUG DOSE; MEAN ARTERIAL PRESSURE; MYOCARDITIS; PRIORITY JOURNAL; REVIEW;

ADOLESCENT; CARDIOVASCULAR AGENTS; CARDIOVASCULAR DISEASES; CHILD; CHILD, PRESCHOOL; COMBINED MODALITY THERAPY; CRITICAL ILLNESS; DIURETICS; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; EXTRACORPOREAL MEMBRANE OXYGENATION; HUMANS; INFANT; INFANT, NEWBORN; TREATMENT OUTCOME;

EID: 80051795830     PISSN: 01602446     EISSN: 15334023     Source Type: Journal    
DOI: 10.1097/FJC.0b013e318213aac2     Document Type: Review

References (77)

1. Pasquali SK, Hall M, Slonim AD, et al. Off-label use of cardiovascular medications in children hospitalized with congenital and acquired heart disease. Circ Cardiovasc Qual Outcomes. 2008;1:74-83.
2. Moller JH. Perspectives in Pediatric Cardiology: Surgery of Congenital Heart Disease: Pediatric Cardiac Care Consortium, 1984-1995. Vol. 6. Armonk, NY: Futura Publishing Company; 1998.
3. Lloyd-Jones D, Adams RJ, Brown TM, et al. Heart disease and stroke statistics-2010 update: A report from the American Heart Association. Circulation. 2010;121:e46-e215.
4. Ohye RG, Sleeper LA, Mahony L, et al. Comparison of shunt types in the Norwood procedure for single-ventricle lesions. N Engl J Med. 2010;362: 1980-1992.
5. Bartlett RH, Gazzaniga AB, Jefferies MR, et al. Extracorporeal membrane oxygenation (ECMO) cardiopulmonary support in infancy. Trans Am Soc Artif Intern Organs. 1976;22:80-93.
6. Group UCET. UK collaborative randomised trial of neonatal extracorporeal membrane oxygenation. UK Collaborative ECMO Trial Group. Lancet. 1996;348:75-82.
7. Peek GJ, Mugford M, Tiruvoipati R, et al. Efficacy and economic assessment of conventional ventilatory support versus extracorporeal membrane oxygenation for severe adult respiratory failure (CESAR): A multicentre randomised controlled trial. Lancet. 2009;374:1351-1363.
8. Extracorporeal Life Support Organization (ELSO). ECLS Registry Report: International Summary. January 2010.
9. Barnes S, Shields B, Bonney W, et al. The pediatric cardiology pharmacopoeia: 2004 update. Pediatr Cardiol. 2004;25:623-646.
10. Moss AJ, Allen HD. Moss and Adams' Heart Disease in Infants, Children, and Adolescents: Including the Fetus and Young Adult. 7th ed. Philadelphia, PA: Wolters Kluwer Health/Lippincott Williams & Wilkins; 2008.
11. Buck ML. Pharmacokinetic changes during extracorporeal membrane oxygenation: Implications for drug therapy of neonates. Clin Pharmacokinet. 2003;42:403-417.
12. Southgate WM, DiPiro JT, Robertson AF. Pharmacokinetics of gentamicin in neonates on extracorporeal membrane oxygenation. Antimicrob Agents Chemother. 1989;33:817-819.
13. Cohen P, Collart L, Prober CG, et al. Gentamicin pharmacokinetics in neonates undergoing extracorporal membrane oxygenation. Pediatr Infect Dis J. 1990;9:562-566.
14. Dodge WF, Jelliffe RW, Zwischenberger JB, et al. Population pharmacokinetic models: Effect of explicit versus assumed constant serum concentration assay error patterns upon parameter values of gentamicin in infants on and off extracorporeal membrane oxygenation. Ther Drug Monit. 1994;16:552-559.
15. Bhatt-Mehta V, Johnson CE, Schumacher RE. Gentamicin pharmacokinetics in term neonates receiving extracorporeal membrane oxygenation. Pharmacotherapy. 1992;12:28-32.
16. Munzenberger PJ, Massoud N. Pharmacokinetics of gentamicin in neonatal patients supported with extracorporeal membrane oxygenation. ASAIO Trans. 1991;37:16-18.
17. Hoie EB, Swigart SA, Leuschen MP, et al. Vancomycin pharmacokinetics in infants undergoing extracorporeal membrane oxygenation. Clin Pharm. 1990;9:711-715.
18. Amaker RD, DiPiro JT, Bhatia J. Pharmacokinetics of vancomycin in critically ill infants undergoing extracorporeal membrane oxygenation. Antimicrob Agents Chemother. 1996;40:1139-1142.
19. Buck ML. Vancomycin pharmacokinetics in neonates receiving extracorporeal membrane oxygenation. Pharmacotherapy. 1998;18: 1082-1086.
20. Bhatt-Meht V, Annich G. Sedative clearance during extracorporeal membrane oxygenation. Perfusion. 2005;20:309-315.
21. Dagan O, Klein J, Bohn D, et al. Effects of extracorporeal membrane oxygenation on morphine pharmacokinetics in infants. Crit Care Med. 1994;22:1099-1101.
22. Mehta NM, Halwick DR, Dodson BL, et al. Potential drug sequestration during extracorporeal membrane oxygenation: Results from an ex vivo experiment. Intensive Care Med. 2007;33:1018-1024.
23. Mulla H, Lawson G, von Anrep C, et al. In vitro evaluation of sedative drug losses during extracorporeal membrane oxygenation. Perfusion. 2000;15:21-26.
24. Wildschut E, ed. Drug Therapies in Neonates and Children During Extracorporeal Membrane Oxygenation (ECMO); Keep your Eyes Open. Rotterdam, The Netherlands: Erasmus MC; 2010.
25. Dagan O, Klein J, Gruenwald C, et al. Preliminary studies of the effects of extracorporeal membrane oxygenator on the disposition of common pediatric drugs. Ther Drug Monit. 1993;15:263-266.
26. Rosen DA, Rosen KR, Silvasi DL. In vitro variability in fentanyl absorption by different membrane oxygenators. J Cardiothorac Anesth. 1990;4:332-335.
27. Amaker RD, Bhatia J. ECMO and pharmacotherapy. Neonatal Netw. 1996;15:58.
28. Wells TG, Fasules JW, Taylor BJ, et al. Pharmacokinetics and pharmacodynamics of bumetanide in neonates treated with extracorporeal membrane oxygenation. J Pediatr. 1992;121:974-980.
29. Ahsman MJ, ed. Determinants of Pharmacokinetic Variability During Extracorporeal Membrane Oxygentation: A Roadmap to Rational Pharmacotherapy in Children. Rotterdam, The Netherlands: Erasmus MC; 2010.
30. Mulrow JP, Crawford MH. Clinical pharmacokinetics and therapeutic use of hydralazine in congestive heart failure. Clin Pharmacokinet. 1989;16: 86-89.
31. Plumpton K, Justo R, Haas N. Amiodarone for post-operative junctional ectopic tachycardia. Cardiol Young. 2005;15:13-18.
32. Trippel DL, Wiest DB, Gillette PC. Cardiovascular and antiarrhythmic effects of esmolol in children. J Pediatr. 1991;119(1 pt 1):142-147.
33. Kendrick JG, Macready JJ, Kissoon N. Amiodarone treatment of junctional ectopic tachycardia in a neonate receiving extracorporeal membrane oxygenation. Ann Pharmacother. 2006;40:1872-1875.
34. Taketomo C, Hodding JH, Kraus DH, eds. Pediatric Dosage Handbook. Lexicomp's Drug Reference Handbooks. 16th ed. Hudson, OH: Lexi- Comp; 2009.
35. Behera SK, Zuccaro JC, Wetzel GT, et al. Nesiritide improves hemodynamics in children with dilated cardiomyopathy: A pilot study. Pediatr Cardiol. 2009;30:26-34.
36. Jefferies JL, Denfield SW, Price JF, et al. A prospective evaluation of nesiritide in the treatment of pediatric heart failure. Pediatr Cardiol. 2006; 27:402-407.
37. Jefferies JL, Price JF, Denfield SW, et al. Safety and efficacy of nesiritide in pediatric heart failure. J Card Fail. 2007;13:541-548.
38. Ryan A, Rosen DA, Tobias JD. Preliminary experience with nesiritide in pediatric patients less than 12 months of age. J Intensive Care Med. 2008; 23:321-328.
39. Marcus LS, Hart D, Packer M, et al. Hemodynamic and renal excretory effects of human brain natriuretic peptide infusion in patients with congestive heart failure. A double-blind, placebo-controlled, randomized crossover trial. Circulation. 1996;94:3184-3189.
40. Sell LL, Cullen ML, Lerner GR, et al. Hypertension during extracorporeal membrane oxygenation: Cause, effect, and management. Surgery. 1987; 102:724-730.
41. McBride BF, White CM, Campbell M, et al. Nicardipine to control neonatal hypertension during extracorporeal membrane oxygen support. Ann Pharmacother. 2003;37:667-670.
42. Flynn JT, Pasko DA. Calcium channel blockers: Pharmacology and place in therapy of pediatric hypertension. Pediatr Nephrol. 2000;15:302-316.
43. Gouyon JB, Geneste B, Semama DS, et al. Intravenous nicardipine in hypertensive preterm infants. Arch Dis Child Fetal Neonatal Ed. 1997;76: F126-F127.
44. Smith T, Rosen DA, Russo P, et al. Nesiritide during extracorporeal membrane oxygenation. Paediatr Anaesth. Feb 2005;15:152-157.
45. Flynn JT, Mottes TA, Brophy PD, et al. Intravenous nicardipine for treatment of severe hypertension in children. J Pediatr. 2001;139: 38-43.
46. van der Vorst MM, den Hartigh J, et al. An exploratory study with an adaptive continuous intravenous furosemide regimen in neonates treated with extracorporeal membrane oxygenation. Crit Care. 2007;11:R111.
47. van der Vorst MM, Wildschut E, Houmes RJ, et al. Evaluation of furosemide regimens in neonates treated with extracorporeal membrane oxygenation. Crit Care. 2006;10:R168.
48. Baquero H, Soliz A, Neira F, et al. Oral sildenafil in infants with persistent pulmonary hypertension of the newborn: A pilot randomized blinded study. Pediatrics. 2006;117(4):1077-1083.
49. Humpl T, Reyes JT, Holtby H, et al. Beneficial effect of oral sildenafil therapy on childhood pulmonary arterial hypertension: Twelve-month clinical trial of a single-drug, open-label, pilot study. Circulation. 2005; 111:3274-3280.
50. Karatza AA, Bush A, Magee AG. Safety and efficacy of Sildenafil therapy in children with pulmonary hypertension. Int J Cardiol. 2005;100:267-273.
51. Karatza AA, Narang I, Rosenthal M et al. Treatment of primary pulmonary hypertension with oral sildenafil. Respiration. 2004;71:192-194.
52. Stone DM, Frattarelli DA, Karthikeyan S, et al. Altered prostaglandin E1 dosage during extracorporeal membrane oxygenation in a newborn with ductal-dependent congenital heart disease. Pediatr Cardiol. 2006;27: 360-363.
53. Cuneo BF, Zales VR, Blahunka PC, et al. Pharmacodynamics and pharmacokinetics of esmolol, a short-acting beta-blocking agent, in children. Pediatr Cardiol. 1994;15:296-301.
54. Robinson B, Eshaghpour E, Ewing S, et al. Hypertrophic obstructive cardiomyopathy in an infant of a diabetic mother: Support by extracorporeal membrane oxygenation and treatment with beta-adrenergic blockade and increased intravenous fluid administration. ASAIO J. 1998; 44:845-847.
55. Figa FH, Gow RM, Hamilton RM, et al. Clinical efficacy and safety of intravenous Amiodarone in infants and children. Am J Cardiol. 1994;74: 573-577.
56. Perry JC, Fenrich AL, Hulse JE, et al. Pediatric use of intravenous amiodarone: Efficacy and safety in critically ill patients from a multicenter protocol. J Am Coll Cardiol. 1996;27:1246-1250.
57. Falik R, Flores BT, Shaw L, et al. Relationship of steady-state serum concentrations of amiodarone and desethylamiodarone to therapeutic efficacy and adverse effects. Am J Med. 1987;82:1102-1108.
58. Haffajee CI, Love JC, Canada AT, et al. Clinical pharmacokinetics and efficacy of amiodarone for refractory tachyarrhythmias. Circulation. 1983;67:1347-1355.
59. Latini R, Tognoni G, Kates RE. Clinical pharmacokinetics of amiodarone. Clin Pharmacokinet. 1984;9:136-156.
60. Naccarelli GV, Rinkenberger RL, Dougherty AH, et al. Amiodarone: Pharmacology and antiarrhythmic and adverse effects. Pharmacotherapy. 1985;5:298-313.
61. Burri S, Hug MI, Bauersfeld U. Efficacy and safety of intravenous amiodarone for incessant tachycardias in infants. Eur J Pediatr. 2003;162: 880-884.
62. Martin GR, Chauvin L, Short BL. Effects of hydralazine on cardiac performance in infants receiving extracorporeal membrane oxygenation. J Pediatr. 1991;118:944-948.
63. Milou C, Debuche-Benouachkou V, Semama DS, et al. Intravenous nicardipine as a first-line antihypertensive drug in neonates. Intensive Care Med. 2000;26:956-958.
64. Tobias JD. Nicardipine to control mean arterial pressure after cardiothoracic surgery in infants and children. Am J Ther. 2001;8:3-6.
65. Simsic JM, Mahle WT, Cuadrado A, et al. Hemodynamic effects and safety of nesiritide in neonates with heart failure. J Intensive Care Med. 2008;23:389-395.
66. Tobias JD, Pietsch JB, Lynch A. Nicardipine to control mean arterial pressure during extracorporeal membrane oxygenation. Paediatr Anaesth. 1996;6:57-60.
67. Klinge JM, Scharf J, Hofbeck M, et al. Intermittent administration of furosemide versus continuous infusion in the postoperative management of children following open heart surgery. Intensive Care Med. 1997;23: 693-697.
68. Luciani GB, Nichani S, Chang AC, et al. Continuous versus intermittent furosemide infusion in critically ill infants after open heart operations. Ann Thorac Surg. 1997;64:1133-1139.
69. Martin SJ, Danziger LH. Continuous infusion of loop diuretics in the critically ill: A review of the literature. Crit Care Med. 1994;22:1323-1329.
70. Singh NC, Kissoon N, al Mofada S, et al. Comparison of continuous versus intermittent furosemide administration in postoperative pediatric cardiac patients. Crit Care Med. 1992;20:17-21.
71. van der Vorst MM, Ruys-Dudok van Heel I, Kist-van Holthe JE, et al. Continuous intravenous furosemide in haemodynamically unstable children after cardiac surgery. Intensive Care Med. 2001;27:711-715.
72. Wells TG. The pharmacology and therapeutics of diuretics in the pediatric patient. Pediatr Clin North Am. 1990;37:463-504.
73. Sullivan JE, Witte MK, Yamashita TS, et al. Pharmacokinetics of bumetanide in critically ill infants. Clin Pharmacol Ther. 1996;60: 405-413.
74. Hamberg M, Samuelsson B. On the metabolism of prostaglandins E1 and E2 in man. J Biol Chem. 1971;246:6713-6721.
75. Rosenkranz B, Fischer C, Boeynaems JM, et al. Metabolic disposition of prostaglandin E1 in man. Biochim Biophys Acta. 1983;750:231-236.
76. de Hoog M, Mouton JW, van den Anker JN. Vancomycin: Pharmacokinetics and administration regimens in neonates. Clin Pharmacokinet. 2004;43:417-440.
77. Mulla H, Pooboni S. Population pharmacokinetics of vancomycin in patients receiving extracorporeal membrane oxygenation. Br J Clin Pharmacol. 2005;60:265-275.